Abstract
Macroeconomic variables primarily related to the health care system are the result of two key factors. On the one hand, the results obtained for preserving the health of individuals improving, also, the quality of life and, on the other hand, the costs to be supported in order to reach these results. There is evidence that a balance between these two parameters must be obtained in an era of limited economic resources and, therefore, measures, which can achieve these variables, are under study.
Cost-effectiveness ratio is the most economic factor analyzed still lending to define the relationship between costs and disease. With regard to cardiovascular risk, budgets not always in line with established expectations are under exam.
Quantitative measures related to cost-effectiveness ratio as the estimate-score system, which sets specific scores for the symptoms of the disease, are studied to improve the budget that regulates costs and results on public health including cardiovascular risk characterized by a high frequency of adverse events.
Keywords: Economic costs, cost-effectiveness ratio, cardiovascular risk, health care system, budgets, parameters, estimate-score system, economic resources, balance, parameters
Current Pharmaceutical Design
Title:The Economic Costs for the Control of Cardiovascular Risk: An Overview
Volume: 19 Issue: 13
Author(s): Aldo Leone
Affiliation:
Keywords: Economic costs, cost-effectiveness ratio, cardiovascular risk, health care system, budgets, parameters, estimate-score system, economic resources, balance, parameters
Abstract: Macroeconomic variables primarily related to the health care system are the result of two key factors. On the one hand, the results obtained for preserving the health of individuals improving, also, the quality of life and, on the other hand, the costs to be supported in order to reach these results. There is evidence that a balance between these two parameters must be obtained in an era of limited economic resources and, therefore, measures, which can achieve these variables, are under study.
Cost-effectiveness ratio is the most economic factor analyzed still lending to define the relationship between costs and disease. With regard to cardiovascular risk, budgets not always in line with established expectations are under exam.
Quantitative measures related to cost-effectiveness ratio as the estimate-score system, which sets specific scores for the symptoms of the disease, are studied to improve the budget that regulates costs and results on public health including cardiovascular risk characterized by a high frequency of adverse events.
Export Options
About this article
Cite this article as:
Leone Aldo, The Economic Costs for the Control of Cardiovascular Risk: An Overview, Current Pharmaceutical Design 2013; 19 (13) . https://dx.doi.org/10.2174/1381612811319130013
DOI https://dx.doi.org/10.2174/1381612811319130013 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cardiac Effects of HDL and Its Components on Diabetic Cardiomyopathy
Endocrine, Metabolic & Immune Disorders - Drug Targets Carotid Endarterectomy and Carotid Artery Stenting Lead to Improved Cognitive Performance in Patients with Severe Carotid Artery Stenosis
Current Neurovascular Research Prophylactic Potential of Conventional and Supercritical Garlic Extracts to Alleviate Diet Related Malfunctions
Recent Patents on Food, Nutrition & Agriculture Hypertension and Angiogenesis
Current Pharmaceutical Design Ryanodine Receptor - A Novel Therapeutic Target in Heart Disease
Recent Patents on Cardiovascular Drug Discovery Agents for the Inhibition of Cholesteryl Ester Transfer Protein (CETP) and Prospects for the Future Treatment of Atherosclerosis
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Hematopoietic Stem Cells Therapies
Current Stem Cell Research & Therapy Respiratory Syncytial Virus (RSV) Prevention and Treatment: Past, Present, and Future
Cardiovascular & Hematological Agents in Medicinal Chemistry Synthesis and Evaluation of Compounds Containing 4-arylpiperazinyl Moieties Linked to a 2-(pyridin-3-yl)-1H-benzimidazole as p38 MAP Kinase Inhibitors
Letters in Drug Design & Discovery Tocotrienols and Cardiovascular Health
Current Pharmaceutical Design Control of Risk Factors for Cardiovascular Disease among Multinational Patient Population in the Arabian Gulf
Current Vascular Pharmacology The Role of Intracellular 35-Cyclic Adenosine Monophosphate (cAMP) in Atherosclerosis
Current Vascular Pharmacology Female Infertility and Cardiovascular Risk - A Hype or an Underestimated Reality?
Current Pharmaceutical Design Translational Multimodality Neuroimaging
Current Drug Targets Pindolol Augmentation of Antidepressant Response
Current Drug Targets Recent Advances in the Synthesis of Biologically Active Cinnoline, Phthalazine and Quinoxaline Derivatives
Current Organic Chemistry A Role for Rev-erbα Ligands in the Regulation of Adipogenesis
Current Pharmaceutical Design Pharmacogenetics in Cardiovascular Antithrombotic Therapy
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Cranberry: A Promising Natural Source of Potential Nutraceuticals with Anticancer Activity
Anti-Cancer Agents in Medicinal Chemistry Role of Molecular Analysis After Autopsy Negative Sudden Death in the Young
Current Pediatric Reviews